SunTrust Banks, Inc. reaffirmed their buy rating on shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) in a research note published on Tuesday morning, MarketBeat Ratings reports. They currently have a $80.00 price target on the biopharmaceutical company’s stock, up from their previous price target of $68.00. SunTrust Banks also issued estimates for Agios Pharmaceuticals’ Q3 2017 earnings at ($1.78) EPS, Q4 2017 earnings at ($1.77) EPS, FY2017 earnings at ($6.92) EPS, FY2019 earnings at ($5.80) EPS, FY2020 earnings at ($4.90) EPS and FY2021 earnings at ($1.80) EPS.

AGIO has been the topic of a number of other reports. Oppenheimer Holdings, Inc. set a $75.00 price objective on Agios Pharmaceuticals and gave the company a buy rating in a research report on Sunday, June 11th. ValuEngine upgraded Agios Pharmaceuticals from a strong sell rating to a sell rating in a research report on Friday, June 2nd. Zacks Investment Research upgraded Agios Pharmaceuticals from a sell rating to a hold rating in a research report on Friday, April 28th. Canaccord Genuity set a $90.00 price objective on Agios Pharmaceuticals and gave the company a buy rating in a research report on Thursday, May 18th. Finally, Cann reiterated a buy rating and issued a $75.00 price objective on shares of Agios Pharmaceuticals in a research report on Wednesday, April 19th. Five equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Agios Pharmaceuticals presently has an average rating of Buy and an average target price of $74.75.

Agios Pharmaceuticals (AGIO) traded up 1.03% during mid-day trading on Tuesday, hitting $58.86. The stock had a trading volume of 501,674 shares. The firm’s market cap is $2.85 billion. Agios Pharmaceuticals has a 1-year low of $35.84 and a 1-year high of $67.74. The stock has a 50 day moving average of $56.90 and a 200-day moving average of $51.87.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.57) by $0.21. The business had revenue of $11.30 million for the quarter, compared to the consensus estimate of $10.68 million. Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The firm’s revenue was up 62.1% on a year-over-year basis. During the same quarter last year, the company earned ($1.47) earnings per share. Analysts predict that Agios Pharmaceuticals will post ($6.90) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was originally published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://theolympiareport.com/2017/08/12/agios-pharmaceuticals-inc-nasdaqagio-receives-buy-rating-from-suntrust-banks-inc.html.

In other news, CEO David P. Schenkein sold 27,000 shares of the firm’s stock in a transaction on Wednesday, August 2nd. The stock was sold at an average price of $59.95, for a total value of $1,618,650.00. Following the transaction, the chief executive officer now directly owns 3,000 shares in the company, valued at approximately $179,850. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO David P. Schenkein sold 3,000 shares of the firm’s stock in a transaction on Wednesday, June 7th. The stock was sold at an average price of $50.02, for a total value of $150,060.00. Following the completion of the transaction, the chief executive officer now owns 1,100 shares in the company, valued at $55,022. The disclosure for this sale can be found here. Insiders sold a total of 79,120 shares of company stock worth $4,557,207 over the last 90 days. 10.55% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. C WorldWide Group Holding A S bought a new position in Agios Pharmaceuticals during the first quarter valued at about $105,000. Bank of Montreal Can raised its position in Agios Pharmaceuticals by 11.7% in the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock valued at $121,000 after buying an additional 216 shares in the last quarter. Blue Sky Asset Management LLC bought a new position in Agios Pharmaceuticals during the first quarter valued at about $129,000. Russell Investments Group Ltd. raised its position in Agios Pharmaceuticals by 163.9% in the first quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock valued at $149,000 after buying an additional 1,583 shares in the last quarter. Finally, Advantage Investment Management LLC raised its position in Agios Pharmaceuticals by 109.7% in the first quarter. Advantage Investment Management LLC now owns 3,250 shares of the biopharmaceutical company’s stock valued at $190,000 after buying an additional 1,700 shares in the last quarter. Institutional investors and hedge funds own 84.53% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.